Effectiveness and safety of anti-CD20 monoclonal antibodies versus csDMARDs in anti-Jo-1 antisynthetase syndrome: A retrospective cohort study
Authors' conclusion
CD20mAbs exhibited remarkable treatment efficacy and acceptable safety in patients with Jo1+ASyS.
Study context
- Population
- Patients with anti-Jo-1 ASyS, RenJi Hospital, China (2007–2023)49 matched pairs of prescriptions
- Participants
- 128 patients
- Exposure
- Anti-CD20 monoclonal antibodies vs csDMARDs
- Outcome
- Percentage reaching 5-item LDA (no active arthritis, myositis, ILD, fever, and prednisone ≤7.5 mg/day)
Methodological detailssingle-centre, prevalent new-user design, time-based propensity-score matched, without replacement
- Single-centre
- Prevalent new-user design
- Time-based propensity-score matched, without replacement
Main finding
As reported in the abstract
LDA
P = 0.011
Observational data: associations, not effects.
Further findings
Sensitivity analyses
- Confirmed robustness of superior effectiveness of CD20mAbs vs csDMARDs
Safety
Per 100 patient-yr
| Outcome | CD20mAbs | csDMARDs | RR (95 % CI) | |
|---|---|---|---|---|
| Major infections, exposure-adjusted incidence rate | 7.911 | 6.479 | 1.22 (0.64–2.36) | |
| 0.512Relative risk (log scale) |
Original publication
Effectiveness and safety of anti-CD20 monoclonal antibodies versus csDMARDs in anti-Jo-1 antisynthetase syndrome: A retrospective cohort study. Semin Arthritis Rheum. Published 13 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →